Hester Biosciences Limited Announces Audited Consolidated Earnings Results for the Year Ended March 31, 2018 and Standalone Earnings Results for Fourth Quarter and Full Year Ended March 31, 2018; Provides Tax Rate Guidance for the Full Year of 2019
May 14, 2018 at 02:22 am
Share
Hester Biosciences Limited announced audited standalone earnings results for fourth quarter and full year ended March 31, 2018 and consolidated earnings for the full year ended March 31, 2018. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 374.83 million, profit before tax of INR 94.41 million, profit for the period of INR 90.14 million or INR 10.59 per basic and diluted share compared to the net sales/income from operations of INR 355.96 million, profit before tax of INR 93.69 million, profit for the period of INR 71.10 million or INR 8.32 per basic and diluted share for the same quarter a year ago.
For the year, on standalone basis, on standalone basis, the company reported net sales/income from operations of INR 1,352.53 million, profit before tax of INR 437.07 million, profit for the period of INR 305.58 million or INR 35.92 per basic and diluted share compared to the net sales/income from operations of INR 1,255.79 million, profit before tax of INR 330.87 million, profit for the period of INR 249.40 million or INR 29.32 per basic and diluted share for the same quarter a year ago.
For the year, on consolidated basis, the company reported net sales/income from operations of INR 1,364.05 million, profit before tax of INR 361.21 million, profit for the period of INR 230.67 million or INR 27.12 per basic and diluted share compared to the net sales/income from operations of INR 1,254.03 million, profit before tax of INR 309.34 million, profit for the period of INR 227.87 million or INR 26.79 per basic and diluted share for the same quarter a year ago.
For the full year of 2019, the company expects tax rate would be the 25%.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
Hester Biosciences Limited Announces Audited Consolidated Earnings Results for the Year Ended March 31, 2018 and Standalone Earnings Results for Fourth Quarter and Full Year Ended March 31, 2018; Provides Tax Rate Guidance for the Full Year of 2019